IFNAR1-dependent metabolic circuit drives pathogenic neutrophil activation in chronic mucosal inflammation

Neutrophils are double-edged effectors of the innate immune system: while essential for host defense, they can drive significant tissue damage in the context of chronic inflammatory diseases. Identifying strategies to selectively dampen their pathogenic functions without compromising antimicrobial immunity remains a major clinical challenge. Here, we define a conserved IFNAR1-driven circuit mediated by iron homeostasis that sustains neutrophil pathogenicity across distinct mucosal tissues. Using single-cell transcriptomics and a CRISPR-based functional screen, we identified the mitochondrial iron transporter Mitoferrin-1 (SLC25A37) as a key regulator of neutrophil inflammatory programming. Mechanistically, our data indicate that Mitoferrin-1 mediates a feedforward loop in which NET-derived histones activate toll-like receptor 9 (TLR9), which in turn sustains IFN-α/IFNAR1 signaling, rewires mitochondrial metabolism, and ultimately drives tissue damage through markedly increased of NETosis, reactive oxygen species production, and degranulation. Notably, this IFNAR1-driven inflammatory circuit operates entirely independently of antimicrobial function, as pharmacological IFNAR1 blockade fully preserves phagocytic activity against bacterial pathogens in vivo. Targeting this pathway selectively attenuates neutrophil-driven inflammation in both murine models of colitis and acute lung injury, as well as in primary human intestinal organoid systems. Together, these findings identify a targetable metabolic node for selectively disarming pathogenic neutrophil responses in the setting of chronic inflammatory disease.

Authors

Institutions

Publication Details

Journal
Signal Transduction and Targeted Therapy
Published
2026-09-13
DOI
https://doi.org/10.1038/s41392-026-02963-3
Primary Topic
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

IFNAR1-dependent metabolic circuit drives pathogenic neutrophil activation in chronic mucosal inflammation

Cecília Pessoa Rodrigues, Oliver Soehnlein, Raquel R. Calçada, Daniel Regan-Komito et al.
Signal Transduction and Targeted Therapy
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
article

IFNAR1-dependent metabolic circuit drives pathogenic neutrophil activation in chronic mucosal inflammation

Cecília Pessoa Rodrigues, Oliver Soehnlein, Raquel R. Calçada, Daniel Regan-Komito, Ece Yıldız, Marvin Hering, Kara G. Lassen, Anja Scheidegger, Lukas Kaltenbach, Alina Gavrilov, Mika Manser, Emma Doran, Julian Behr, Daniela Liberati, Tamara Hoening, Markus Martin Kramberg, Anna Mechling, Sharang Kulkarni, Mairene Coto-Llerena, Mafalda Arnaud, Leon Sidney Strauss
article en

Abstract

Neutrophils are double-edged effectors of the innate immune system: while essential for host defense, they can drive significant tissue damage in the context of chronic inflammatory diseases. Identifying strategies to selectively dampen their pathogenic functions without compromising antimicrobial immunity remains a major clinical challenge. Here, we define a conserved IFNAR1-driven circuit mediated by iron homeostasis that sustains neutrophil pathogenicity across distinct mucosal tissues. Using single-cell transcriptomics and a CRISPR-based functional screen, we identified the mitochondrial iron transporter Mitoferrin-1 (SLC25A37) as a key regulator of neutrophil inflammatory programming. Mechanistically, our data indicate that Mitoferrin-1 mediates a feedforward loop in which NET-derived histones activate toll-like receptor 9 (TLR9), which in turn sustains IFN-α/IFNAR1 signaling, rewires mitochondrial metabolism, and ultimately drives tissue damage through markedly increased of NETosis, reactive oxygen species production, and degranulation. Notably, this IFNAR1-driven inflammatory circuit operates entirely independently of antimicrobial function, as pharmacological IFNAR1 blockade fully preserves phagocytic activity against bacterial pathogens in vivo. Targeting this pathway selectively attenuates neutrophil-driven inflammation in both murine models of colitis and acute lung injury, as well as in primary human intestinal organoid systems. Together, these findings identify a targetable metabolic node for selectively disarming pathogenic neutrophil responses in the setting of chronic inflammatory disease.

Signal Transduction and Targeted TherapyVol. 11(1)
Roche (Switzerland) (CH), University of Münster (DE)
Good health and well-being
Openalex Percentile: Top 17%
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.